Few women initiate systemic hormone therapy for menopausal symptoms, and the majority of patients who do discontinue treatment within the first year.

Cardiovascular outcomes do not differ significantly by sex among patients receiving tirzepatide for obesity and heart failure.

Deep-seated systemic and implicit racial biases within health care education, clinical decision-making, and diagnostic practices continue to drive persistent disparities in patient outcomes for people ...

For adults with T2D receiving SGLT2is, risk factors for ketoacidosis include high HbA1c, previous ketoacidosis, and recent hypoglycemia.

The FDA has granted Priority Review to Alexion's BLA for efzimfotase alfa, a biweekly enzyme replacement therapy for hypophosphatasia.

COVID-19 infection is associated with a lower risk for developing type 1 diabetes (T1D) in individuals younger than 30 years.

The Endocrine Society successfully blocked an FTC subpoena regarding its gender-affirming care guidelines following a federal court injunction.